Breaking News
February 18, 2018 - Scientists develop green chemistry method to improve pharmaceutical manufacturing efficiency
February 17, 2018 - ‘A Time Clock to a Tissue Clock’ for Acute Stroke Care
February 17, 2018 - Cancer Care Gets Personal | NIH News in Health
February 17, 2018 - Do more youth use or do youth use more?
February 17, 2018 - Eating faster linked to obesity
February 17, 2018 - Who’s Still Smoking? ACS Report Highlights Most Vulnerable Adults
February 17, 2018 - Study of smoking and genetics illuminates complexities of blood pressure
February 17, 2018 - Study reveals new link between bone cells and blood glucose level
February 17, 2018 - Children with reading challenges may have lower than expected binocular vision test results
February 17, 2018 - Mass Shootings Trigger Change for Emergency Medicine
February 17, 2018 - ECMO helps revive woman thought to be drowned
February 17, 2018 - Learning stress-reducing techniques may benefit people with epilepsy
February 17, 2018 - Shedding Pounds Before Weight-Loss Surgery a Smart Move
February 17, 2018 - FDA Approves New Cystic Fibrosis Drug Combo
February 17, 2018 - Augmented Reality helps surgeons to ‘see through’ tissue and reconnect blood vessels
February 17, 2018 - Emotional state affects operation of the entire brain instead of being restricted to specific regions
February 17, 2018 - Apalutamide Slows Metastasis in Prostate Cancer
February 17, 2018 - Kids’ well visits linked to lower appendicitis complications
February 17, 2018 - New NK cell-based immunotherapy effective against several types of leukemia
February 17, 2018 - Producing Super-Swelled Lyotropic Crystals for Drug Development
February 17, 2018 - Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
February 17, 2018 - Molecular Imaging Flags Risk of AAA Rupture
February 17, 2018 - Researchers identify risk factors for sleep apnea during pregnancy
February 17, 2018 - More work required to find the right drug dosage for pediatric patients
February 17, 2018 - Factors ID’d That Predict RA Remission with Etanercept
February 17, 2018 - A handout or a hand up? How we judge others guides how we help others
February 17, 2018 - ACR receives grant to focus on projects that reduce health disparities
February 17, 2018 - Pimavanserin Might Be Safer Alternative to Ease Dementia Psychosis
February 17, 2018 - Risks of Lung Screening Seen Outweighing Benefits in Many with Smoking History
February 17, 2018 - The impact of Hurricane Harvey on pregnant moms
February 17, 2018 - Gene editing tool used to detect cancer
February 17, 2018 - Researchers detail molecular atlas of cells that form brain’s blood vessels
February 17, 2018 - TUM scientists observe formation of myelin sheaths around nerve fibers
February 17, 2018 - Worst Flu Season Yet? | Medpage Today
February 17, 2018 - Finding the root cause of bronchiolitis symptoms
February 17, 2018 - Climbing stairs reduces hypertension and strengthens muscles
February 17, 2018 - Nature paper unveils bacterial division
February 16, 2018 - Postoperative pain control following extensive pelvic exenteration
February 16, 2018 - Daré Bioscience, Inc. Enters into License and Collaboration Agreement for a Product with the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder
February 16, 2018 - Havana Embassy Staff: ‘Concussion Without Concussion’?
February 16, 2018 - Family impact of congenital Zika syndrome likely to last a lifetime
February 16, 2018 - STI Prevention Helped By Also Discussing Pot, Alcohol Use
February 16, 2018 - New method maps the dopamine system in Parkinson’s patients
February 16, 2018 - Monitoring the Environment of Aseptic Processes
February 16, 2018 - Study finds decline in number of clinical trials funded by NIH
February 16, 2018 - Scientists show connection between sugar chains and bone growth
February 16, 2018 - Researchers develop new method for producing personalized medicine
February 16, 2018 - Women exposed to cleaning products suffer decreased lung function, Study finds
February 16, 2018 - Stem cell vaccine helps protect mice against numerous cancers
February 16, 2018 - Does Your Valentine Have a Roving Eye? Watch Out
February 16, 2018 - All Your MIPS Questions Answered — Sort Of
February 16, 2018 - Mitochondria may protect brain against Parkinson’s
February 16, 2018 - Key proteins could help in controlling the risk of osteoarthritis during aging, Study finds
February 16, 2018 - New review examines effectiveness of cupping therapy in athletes
February 16, 2018 - Resolving Interfacial Protein Dynamics by STReM
February 16, 2018 - Study provides new insights on why healthy children die from flu
February 16, 2018 - Self-sampling followed by HPV testing can benefit women at risk of cervical cancer
February 16, 2018 - Biomedical engineers grow living windpipe structures from self-assembled modules
February 16, 2018 - New device could allow people with disabilities to live more independently, enhance their quality of life
February 16, 2018 - Research identifies gene variants that play key role in how ovarian cancer patients process chemotherapy
February 16, 2018 - iMedicalApps: OB Wheels App Review
February 16, 2018 - To improve self-control, call weight loss what it is: Difficult
February 16, 2018 - Cervical tumors may be vulnerable to therapies that attack cancer’s fuel supply, study shows
February 16, 2018 - Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant – an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
February 16, 2018 - Morning Break: Hello Not-So-Fresh; One Eye, 14 Worms; Foreign Accent Syndrome
February 16, 2018 - New medical advances marking the end of a long reign for ‘diet wizards’
February 16, 2018 - Researchers study how unexpected event makes people to stop an action
February 16, 2018 - Women using short-acting asthma relievers take longer to become pregnant, study shows
February 16, 2018 - Fathers maybe passing on ovarian cancer genes to their daughters
February 16, 2018 - Phonak expands its latest-generation Belong platform with Phonak Naída B, Phonak Sky B hearing aids
February 16, 2018 - FDA Approves Erleada (apalutamide) for Non-Metastatic Castration-Resistant Prostate Cancer
February 16, 2018 - Traces of caffeine and its byproducts in the blood can be indicative of Parkinson’s disease
February 16, 2018 - More Help Needed With Opioid Crisis, Senators Told
February 16, 2018 - Are women really under-represented in clinical trials?
February 16, 2018 - US-based clinical study highlights safety and effectiveness of MENTOR MemoryShape Gel Breast Implants
February 16, 2018 - Higher levels of lifestyle physical activity linked to more gray matter in older adults’ brains
February 16, 2018 - Pfizer to use BC Platforms’ technology solutions to analyze data in cardiovascular diseases
February 16, 2018 - Researchers find shortcomings in pregnancy and prenatal care for women with diabetes
February 16, 2018 - Study could lead to new therapies to improve movement control in stroke survivors
February 16, 2018 - Do Common Household Chemicals Affect Your Weight?
First step toward CRISPR cure of Lou Gehrig’s disease

First step toward CRISPR cure of Lou Gehrig’s disease

image_pdfDownload PDFimage_print
The UC Berkeley team used an adeno-associated virus (AAV) to ferry genes for CRISPR-Cas9 into motor neurons to delay onset of symptoms of ALS in mice. Credit: David Schaffer graphic

University of California, Berkeley scientists have for the first time used CRISPR-Cas9 gene editing to disable a defective gene that causes amyotrophic lateral sclerosis, or Lou Gehrig’s disease, in mice, extending their lifespan by 25 percent.

The therapy delayed the onset of the muscle wasting that characterizes the disease, which results in progressive weakness and eventually proves fatal when the muscles that control breathing fail.

This step toward a CRISPR cure for human ALS will be reported Dec. 20 in the journal Science Advances.

The mice were genetically engineered to express a mutated human gene that in humans causes about 20 percent of all inherited forms of the disease and about 2 percent of all cases of ALS worldwide. Though the genetic cause is not known for all cases of ALS, all are accompanied by the premature death of motor neurons in the brain stem and spinal cord. The neurons allow the brain to control muscles, so loss of this connection means loss of muscle control.

“Being able to rescue motor neurons and motor neuron control over muscle function, especially the diaphragm, is critically important to being able to not only save patients, but also maintain their quality of life,” said senior author David Schaffer, a professor of chemical and biomolecular engineering and director of the Berkeley Stem Cell Center.

The devastating disease usually strikes people between the ages of 40 and 70. An estimated 20,000 Americans are afflicted, and there are no treatments to slow the muscle degeneration.

The UC Berkeley research team used a virus that Schaffer’s team engineered to seek out only motor neurons in the spinal cord and deliver a gene encoding the Cas9 protein into the nucleus. There, the gene was translated into the Cas9 protein, a molecular scissors that cut and disabled the mutant gene responsible for ALS.

In this case, Cas9 was programmed to knock out the mutated gene SOD1 (superoxide dismutase 1. The onset or start of the disease was delayed by almost five weeks, and mice treated by the gene therapy lived about a month longer than the typical four-month lifespan of mice with ALS. Healthy mice can live a couple of years.

The researchers found that, at death, the only surviving motor neuron cells in the mice were those that had been “infected” with the virus and contained Cas9 protein, said Thomas Gaj, a postdoctoral fellow who led the study, now at the University of Illinois at Urbana-Champaign.

“The treatment did not make the ALS mice normal and it is not yet a cure,” Schaffer cautioned. “But based upon what I think is a really strong proof of concept, CRISPR-Cas9 could be a therapeutic molecule for ALS. When we do additional optimization of the delivery to get CRISPR-Cas9 into an even higher percentage of cells, we think we are going to see even better increases in lifespan.”

One of several challenges is to eliminate the SOD1 mutation in other brain and spinal cord cells that support motor neurons. Schaffer’s team is designing a version of the virus – a highly modified adeno-associated virus, or AAV – that will deliver the Cas9 gene to two types of glial cells, astrocytes and oligodendrocytes, that appear to take out neighboring motor neurons, effectively a “bystander effect.”

“I tend to be really cautious, but in this case I would be quite optimistic that if we are able to eliminate SOD1 within not just the neurons but also the astrocytes and supporting glia, I think we are going to see really long extensions of lifespan,” he said.

Schaffer also is working on a self-destruct switch for the Cas9 protein, so that once it knocks out the SOD1 gene, the Cas9 can be eliminated from the cell so as not to accidentally modify other genes or trigger an immune reaction.

Schaffer has been working with the AAV virus for nearly 20 years, evolving it to target specific cells, like motor neurons, without infecting other types of cells. AAV is found in many if not all humans and primates, and appears to be benign.

“We have engineered new AAV vehicles that are capable of high-efficiency delivery to a number of cell and tissue targets in the body, and when CRISPR-Cas9 came along, we viewed it as a wonderful opportunity to put together this incredibly powerful cargo with the ability to carry that cargo to a number of cells and disease targets in vivo,” he said.

A modified AAV is likely to be approved soon by the Food and Drug Administration as a delivery vehicle for a gene therapy against a rare disease called Leber congenital amaurosis type 2, and other therapies delivered by AAV are in the pipeline, Schaffer said.

These therapies are currently based on natural versions of AAV, however, which are not optimized for high-efficiency delivery to most therapeutically important cell targets, so clinicians must either use massive doses or apply the AAV using an invasive surgery. Schaffer has developed technology to engineer viruses for targeted delivery to many cells and tissues following simple routes of administration, for example directly into tissue such as the eye and brain. This led him to cofound a company in 2014, 4D Molecular Therapeutics, to optimize AAV to target any tissue and carry a variety of gene therapies into cells.

“Researchers in the field really know we need better vectors that can target cells through a simple, logical route of administration, and can do so in a very, very efficient way,” he said. “Ours do.”


Explore further:
Researchers devise improved gene-editing process for Duchenne muscular dystrophy

More information:
T. Gaj el al., “In vivo genome editing improves motor function and extends survival in a mouse model of ALS,” Science Advances (2017). advances.sciencemag.org/content/3/12/eaar3952

Journal reference:
Science Advances

Provided by:
University of California – Berkeley

Tagged with:

About author

Related Articles